Drug Design Powered by AI, Driven by Biology

Mission Statement

With biology as our North Star, our mission is to integrate AI, computation, and biological automation to accelerate the design of small molecule and protein therapeutics.

  • Beginning

  • 1976
  • 1990
  • 2003
  • 2018
1st report of sicklecell anemia in theUnited States

We are
Backed By

Selected Investors

Playground Global
Y Combinator
Scientia Ventures
Apollo Projects


We take a biology-first approach to disease target selection and subsequently apply ELVIS™ and ROSALYND™, our AI-driven computational platforms, to accelerate the design of both small molecule drugs and protein therapeutics. Our end-to-end technology powers the full length of early drug discovery, from novel hit discovery to hit-to-lead and lead optimization.

learn more
learn more